Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 9/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20612380 | 0.91 | P2RX7 (0.63) | MAPK1KMT2ACTSKCTSLCTSS | |
| SCHEMBL16466268 | 0.91 | P2RX7 (0.63) | MAPK1KMT2ACTSKCTSLCTSS | |
| SCHEMBL4973030 | 0.91 | P2RX7 (0.54) | MAPK1KMT2ACTSLCTSSP2RX7 | |
| SCHEMBL16466473 | 0.91 | P2RX7 (0.63) | MAPK1KMT2ACTSKCTSLCTSS | |
| SCHEMBL16466559 | 0.89 | CTSL (0.53) | MAPK1KMT2AMEN1CTSLP2RX7 | |
| SCHEMBL16465560 | 0.89 | CTSL (0.53) | MAPK1KMT2AMEN1CTSLP2RX7 | |
| SCHEMBL27145154 | 0.89 | CTSL (0.53) | MAPK1KMT2AMEN1CTSLP2RX7 | |
| SCHEMBL13994324 | 0.88 | MAPK1 (0.58) | MAPK1KMT2AMEN1MAPTCTSK | |
| SCHEMBL9484498 | 0.87 | P2RX7 (0.62) | MAPK1KMT2ACTSKCTSSP2RX7 | |
| SCHEMBL9484504 | 0.87 | P2RX7 (0.62) | MAPK1KMT2ACTSKCTSSP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| EP-1968590-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | MAPK1 1612/4885KMT2A 3532/4885MEN1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.